These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 988964)

  • 101. Sotalol permeability in cultured-cell, rat intestine, and PAMPA system.
    Liu W; Okochi H; Benet LZ; Zhai SD
    Pharm Res; 2012 Jul; 29(7):1768-74. PubMed ID: 22350803
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Assessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthy women.
    Démolis JL; Strabach S; Vacheron F; Funck-Brentano C
    Br J Clin Pharmacol; 2005 Aug; 60(2):120-7. PubMed ID: 16042664
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Therapeutic drug monitoring of antiarrhythmic drugs.
    Jürgens G; Graudal NA; Kampmann JP
    Clin Pharmacokinet; 2003; 42(7):647-63. PubMed ID: 12844326
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects.
    Deneer VH; Lie-A-Huen L; Kingma JH; Proost JH; Kelder JC; Brouwers JR
    Br J Clin Pharmacol; 1998 May; 45(5):485-90. PubMed ID: 9643622
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Stereoselective disposition of (+/-)-sotalol at steady-state conditions.
    Fiset C; Philippon F; Gilbert M; Turgeon J
    Br J Clin Pharmacol; 1993 Jul; 36(1):75-7. PubMed ID: 8373714
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Class III antiarrhythmics in overdose. Presenting features and management principles.
    Leatham EW; Holt DW; McKenna WJ
    Drug Saf; 1993 Dec; 9(6):450-62. PubMed ID: 8129865
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.
    Fitton A; Sorkin EM
    Drugs; 1993 Oct; 46(4):678-719. PubMed ID: 7506652
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Pharmacokinetics of sotalol after chronic administration to patients with renal insufficiency.
    Berglund G; Descamps R; Thomis JA
    Eur J Clin Pharmacol; 1980 Oct; 18(4):321-6. PubMed ID: 7439252
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol.
    Pirttiaho HI; Sotaniemi EA; Pelkonen RO; Pitkänen U; Anttila M; Sundqvist H
    Br J Clin Pharmacol; 1980 Apr; 9(4):399-405. PubMed ID: 7378257
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Fatal sotalol poisoning.
    Montagna M; Groppi A
    Arch Toxicol; 1980 Jan; 43(3):221-6. PubMed ID: 7369870
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Sotalol and metoprolol comparison of their anti-hypertensive effect.
    Andersson O; Berglund G; Descamps R; Thomis J
    Eur J Clin Pharmacol; 1981; 21(2):87-92. PubMed ID: 7341284
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication.
    Neuvonen PJ; Elonen E; Vuorenmaa T; Laakso M
    Eur J Clin Pharmacol; 1981; 20(2):85-9. PubMed ID: 7262178
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Comparison of once and twice daily sotalol in exercise-induced angina pectoris.
    Wilhelmsson C; Vedin A; Ulvenstam G; Aberg A; Descamps R; Thomis JA
    Eur J Clin Pharmacol; 1982; 21(6):461-5. PubMed ID: 7075651
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Pharmacokinetics of propranolol and sotalol in hyperthyroidism.
    Aro A; Anttila M; Korhonen T; Sundquist H
    Eur J Clin Pharmacol; 1982; 21(5):373-7. PubMed ID: 7075642
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Pharmacokinetics of sotalol during pregnancy.
    O'Hare MF; Leahey W; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1983; 24(4):521-4. PubMed ID: 6861867
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Pharmacokinetics of a fixed combination of sotalol and hydrochlorothiazide in hypertensive patients with moderate renal insufficiency.
    Kher A; Fillastre JP; Fourtillan JB; Lefebvre MA; Ingrand I
    Eur J Clin Pharmacol; 1984; 27(3):361-2. PubMed ID: 6510465
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man.
    Hinderling PH; Schmidlin O; Seydel JK
    J Pharmacokinet Biopharm; 1984 Jun; 12(3):263-87. PubMed ID: 6150103
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Binding of beta-adrenoceptor blocking drugs to human serum albumin, to alpha 1-acid glycoprotein and to human serum.
    Belpaire FM; Bogaert MG; Rosseneu M
    Eur J Clin Pharmacol; 1982; 22(3):253-6. PubMed ID: 6125395
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Coronary blood flow and hemodynamic effects of beta-adrenoceptor activation and beta-blockade in the baboon.
    Rosendorff C; Rogers GG; Shimell CJ; Coull A; Bomzon L
    Basic Res Cardiol; 1981; 76(5):545-9. PubMed ID: 6118129
    [No Abstract]   [Full Text] [Related]  

  • 120. Is there a relationship between the physical properties and cardioselectivity of beta-adrenoceptor antagonists?
    Jack DB
    Br J Clin Pharmacol; 1981 Apr; 11(4):402-6. PubMed ID: 6114740
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.